Login Register Cart 0
Generic placeholder image

Current Respiratory Medicine Reviews

Editor-in-Chief

ISSN (Print): 1573-398X
ISSN (Online): 1875-6387

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

The Relationship between Endotypes and Exacerbation Events in COPD Patients

Author(s): Putri Mega Juwita, Muhammad Amin* and Alfian Nur Rosyid

Volume 20, Issue 1, 2024

Published on: 16 October, 2023

Page: [31 - 37] Pages: 7

DOI: 10.2174/011573398X267124231010060918

Price: $65

Abstract

Introduction: Acute exacerbations of COPD are responsible for 60% of health costs, reduce patients' quality of life, and accelerate disease progression. COPD endotypes are expected to provide new insights about clinical phenotypic variability and therapeutic response between individuals through certain biomarker approaches.

Objective: Our study aims to identify the relationship between COPD endotypes and exacerbation events.

Methods: In this cross-sectional study design, participants with stable COPD (n=40) were recruited from the outpatient clinic at Airlangga University Hospital in March-August 2022. Blood was obtained for endotype's biomarker examination, such as α1-antitrypsin (AAT), IL-17A, neutrophil, and eosinophil count. The relationship between COPD endotypes and exacerbation events was analyzed using a non-parametric statistical test.

Result: The lower limit normal of AAT levels obtained was 12.85ng/ml; 47.5% of subjects have low AAT levels. The average IL-17A levels and blood neutrophil counts were 0.478 ± 0.426 pg/ml and 5,916.95 ± 3,581.08 cells/μl, respectively. The average blood eosinophil count was 298.35 ± 280.44 cells/μl, 16 of 40 (40%) subjects with blood eosinophil count > 300 cells/μl. No significant association was observed between AAT levels (p = 1.000), IL-17A levels (p = 0.944), and blood eosinophil count (p = 0.739) with exacerbation events-only blood neutrophil count (p = 0.033) found to have a significant association with exacerbation events in COPD.

Conclusion: AAT levels, IL-17A levels, and blood eosinophil count were not significantly related to exacerbation events in COPD patients. In comparison, blood neutrophil count was the only one associated considerably with exacerbation events. Further research about COPD endotypes is needed to identify exacerbation susceptibility as a precision treatment strategy.

« Previous Next »
Graphical Abstract

[1]
Yudhawati R, Prasetiyo YD. Immunopathogenesis of chronic obstructive pulmonary disease. J Respir 2019; 4(1): 19.
[http://dx.doi.org/10.20473/jr.v4-I.1.2018.19-25]
[2]
Rosyid AN, Maranatha D. Methacholin provocation test in COPD and healthy smokers. Curr Respir Med Rev 2018; 13(3): 168-74.
[http://dx.doi.org/10.2174/1573398X14666180213092735]
[3]
Rosyid AN, Saputra PBT, Purwati DD, et al. Neutrophil elastase in the pathogenesis of chronic obstructive pulmonary disease: A review. Curr Respir Med Rev 2023; 19(1): 29-35.
[http://dx.doi.org/10.2174/1573398X18666220929170117]
[4]
Alonso JLI, Paredes CM. Chronic obstructive pulmonary disease (COPD). Medicine 2018; 12: 3699-709.
[http://dx.doi.org/10.1016/j.med.2018.09.011]
[5]
Nurfaizi A, Marhana IA, Sari GM, Bakhtiar A. Correlation between FEV1% Predicted and Blood Eosinophils in Patients with Exacerbations of Chronic Obstructive Pulmonary Disease (COPD). Jurnal Respirasi 2021; 7(2): 59-64.
[http://dx.doi.org/10.20473/jr.v7-I.2.2021.59-64]
[6]
Keir HR, Dicker A, Lonergan M, et al. Clinical endotypes of exacerbation are associated with differences in microbial composition and diversity in COPD. Eur Respir J 2020; 56(4): 2000391.
[http://dx.doi.org/10.1183/13993003.00391-2020] [PMID: 32444406]
[7]
Siddharthan T, Gupte A, Barnes PJ. Chronic obstructive pulmonary disease endotypes in low- and middle-income country settings: Precision medicine for all. Am J Respir Crit Care Med 2020; 202(2): 171-2.
[http://dx.doi.org/10.1164/rccm.202001-0165ED] [PMID: 32396738]
[8]
Barnes PJ. Endo-phenotyping of COPD patients. Expert Rev Respir Med 2021; 15(1): 27-37.
[http://dx.doi.org/10.1080/17476348.2020.1804364] [PMID: 32730716]
[9]
Garudadri S, Woodruff PG. Targeting chronic obstructive pulmonary disease phenotypes, endotypes, and biomarkers. Ann Am Thorac Soc 2018; 15(S4): S234-8.
[http://dx.doi.org/10.1513/AnnalsATS.201808-533MG] [PMID: 30758998]
[10]
Xiao W, Du L, Mao B, Miao T, Fu J. Endotype-driven prediction of acute exacerbations in chronic obstructive pulmonary disease (EndAECOPD): Protocol for a prospective cohort study. BMJ Open 2019; 9(11): e034592.
[http://dx.doi.org/10.1136/bmjopen-2019-034592] [PMID: 31690612]
[11]
Blanco I, Bueno P, Diego I, et al. Alpha-1 antitrypsin Pi*Z gene frequency and Pi*ZZ genotype numbers worldwide: An update. Int J Chron Obstruct Pulmon Dis 2017; 12: 561-9.
[http://dx.doi.org/10.2147/COPD.S125389] [PMID: 28243076]
[12]
Torres-Durán M, Lopez-Campos JL, Barrecheguren M, et al. Alpha-1 antitrypsin deficiency: Outstanding questions and future directions. Orphanet J Rare Dis 2018; 13(1): 114.
[http://dx.doi.org/10.1186/s13023-018-0856-9] [PMID: 29996870]
[13]
Donato LJ, Snyder MR, Greene DN. Measuring and interpreting serum AAT concentration. Methods Mol Biol 2017; 1639: 21-32.
[http://dx.doi.org/10.1007/978-1-4939-7163-3_3] [PMID: 28752443]
[14]
Janciauskiene S, DeLuca DS, Barrecheguren M, et al. Serum levels of alpha1-antitrypsin and their relationship with COPD in the general spanish population. Arch Bronconeumol 2020; 56(2): 76-83.
[http://dx.doi.org/10.1016/j.arbres.2019.03.001] [PMID: 31153743]
[15]
Takei N, Suzuki M, Makita H, Konno S. Serum alpha-1 antitrypsin levels and the clinical course of chronic obstructive pulmonary disease serum alpha-1 antitrypsin levels and the clinical course of chronic obstructive pulmonary disease Int J Chron Obstruct Pulmon Dis 2019; 14: 2885-93.
[http://dx.doi.org/10.2147/COPD.S225365]
[16]
Reintoft I, Hägerstrand I. alpha 1-antitrypsin deficiency. Arch Pathol Lab Med 1979; 103(9): 486-7.
[http://dx.doi.org/10.1056/NEJMra1910234] [PMID: 313773]
[17]
Smith DJ, Ellis PR, Turner AM. Exacerbations of lung disease in alpha-1 antitrypsin deficiency. Chronic Obstr Pulm Dis 2021; 8(1): 162-76.
[http://dx.doi.org/10.15326/jcopdf.2020.0173] [PMID: 33238089]
[18]
Faria N, Costa MI, Gomes J, Sucena M. What makes Alpha1-antitrypsin deficiency patients exacerbate: A 5-year cohort Monitoring airway disease. European Respiratory Society 2021; p. PA3429.
[http://dx.doi.org/10.1183/13993003.congress-2021.PA3429]
[19]
Choate R, Sandhaus RA, Holm KE, Mannino DM, Strange C. Patient-reported pulmonary symptoms, exacerbations, and management in a cohort of patients with alpha-1 antitrypsin deficiency. Chronic Obstr Pulm Dis 2022; 9(4): 549-61.
[http://dx.doi.org/10.15326/jcopdf.2022.0317] [PMID: 36103189]
[20]
Hiller AM, Piitulainen E, Tanash H. The clinical course of severe alpha-1-antitrypsin deficiency in patients identified by screening. Int J Chron Obstruct Pulmon Dis 2022; 17: 43-52.
[http://dx.doi.org/10.2147/COPD.S340241] [PMID: 35023912]
[21]
Wu HX, Zhuo KQ, Cheng DY. Prevalence and baseline clinical characteristics of eosinophilic chronic obstructive pulmonary disease: A meta-analysis and systematic review. Front Med 2019; 6: 282.
[http://dx.doi.org/10.3389/fmed.2019.00282] [PMID: 31921866]
[22]
Patel BD, Lomas DA. Blood eosinophil thresholds and exacerbations in chronic obstructive pulmonary disease. Genes and Common Diseases 2018; 141: 391-405.
[http://dx.doi.org/10.1016/j.jaci.2018.04.010.Blood]
[23]
Liu M, Wu K, Lin J, et al. Emerging biological functions of IL-17A: A new target in chronic obstructive pulmonary disease? Front Pharmacol 2021; 12: 695957.
[http://dx.doi.org/10.3389/fphar.2021.695957] [PMID: 34305606]
[24]
Christenson SA, van den Berge M, Faiz A, et al. An airway epithelial IL-17A response signature identifies a steroid-unresponsive COPD patient subgroup. J Clin Invest 2018; 129(1): 169-81.
[http://dx.doi.org/10.1172/JCI121087] [PMID: 30383540]
[25]
Yu Y, Zhao L, Xie Y, et al. Th1/th17 cytokine profiles are associated with disease severity and exacerbation frequency in COPD patients. Int J Chron Obstruct Pulmon Dis 2020; 15: 1287-99.
[http://dx.doi.org/10.2147/COPD.S252097] [PMID: 32606639]
[26]
Butler A, Walton GM, Sapey E. Neutrophilic inflammation in the pathogenesis of chronic obstructive pulmonary disease. COPD 2018; 15(4): 392-404.
[http://dx.doi.org/10.1080/15412555.2018.1476475] [PMID: 30064276]
[27]
Lonergan M, Dicker AJ, Crichton ML, et al. Blood neutrophil counts are associated with exacerbation frequency and mortality in COPD. Respir Res 2020; 21(1): 166.
[http://dx.doi.org/10.1186/s12931-020-01436-7] [PMID: 32611352]
[28]
Jasper AE, McIver WJ, Sapey E, Walton GM. Understanding the role of neutrophils in chronic inflammatory airway disease. F1000 Res 2019; 8: 557.
[http://dx.doi.org/10.12688/f1000research.18411.1] [PMID: 31069060]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy